Dex-CSDH randomised, placebo-controlled trial of dexamethasone for chronic subdural haematoma: report of the internal pilot phase

Dex-CSDH trial collaborative and BNTRC collaborative, Ellie Edlmann (Lead / Corresponding author), Eric P. Thelin, Karen Caldwell, Carole Turner, Peter Whitfield, Diederik Bulters, Patrick Holton, Nigel Suttner, Kevin Owusu-Agyemang, Yahia Z. Al-Tamimi, Daniel Gatt, Simon Thomson, Ian A. Anderson, Oliver Richards, Monica Gherle, Emma Toman, Dipankar Nandi, Phillip Kane, Beatrice PantaleoCarol Davis-Wilkie, Silvia Tarantino, Garry Barton, Hani J. Marcus, Aswin Chari, Antonio Belli, Simon Bond, Rafael Gafoor, Sarah Dawson, Lynne Whitehead, Paul Brennan, Ian Wilkinson, Angelos G. Kolias, Peter J. A. Hutchinson

Research output: Contribution to journalArticle

3 Citations (Scopus)
119 Downloads (Pure)

Abstract

The Dex-CSDH trial is a randomised, double-blind, placebo-controlled trial of dexamethasone for patients with a symptomatic chronic subdural haematoma. The trial commenced with an internal pilot, whose primary objective was to assess the feasibility of multi-centre recruitment. Primary outcome data collection and safety were also assessed, whilst maintaining blinding. We aimed to recruit 100 patients from United Kingdom Neurosurgical Units within 12 months. Trial participants were randomised to a 2-week course of dexamethasone or placebo in addition to receiving standard care (which could include surgery). The primary outcome measure of the trial is the modified Rankin Scale at 6 months. This pilot recruited ahead of target; 100 patients were recruited within nine months of commencement. 47% of screened patients consented to recruitment. The primary outcome measure was collected in 98% of patients. No safety concerns were raised by the independent data monitoring and ethics committee and only five patients were withdrawn from drug treatment. Pilot trial data can inform on the design and resource provision for substantive trials. This internal pilot was successful in determining recruitment feasibility. Excellent follow-up rates were achieved and exploratory outcome measures were added to increase the scientific value of the trial.

Original languageEnglish
Article number5885
Pages (from-to)1-13
Number of pages13
JournalScientific Reports
Volume9
DOIs
Publication statusPublished - 10 Apr 2019

Fingerprint Dive into the research topics of 'Dex-CSDH randomised, placebo-controlled trial of dexamethasone for chronic subdural haematoma: report of the internal pilot phase'. Together they form a unique fingerprint.

  • Cite this

    Dex-CSDH trial collaborative and BNTRC collaborative, Edlmann, E., Thelin, E. P., Caldwell, K., Turner, C., Whitfield, P., Bulters, D., Holton, P., Suttner, N., Owusu-Agyemang, K., Al-Tamimi, Y. Z., Gatt, D., Thomson, S., Anderson, I. A., Richards, O., Gherle, M., Toman, E., Nandi, D., Kane, P., ... Hutchinson, P. J. A. (2019). Dex-CSDH randomised, placebo-controlled trial of dexamethasone for chronic subdural haematoma: report of the internal pilot phase. Scientific Reports, 9, 1-13. [5885]. https://doi.org/10.1038/s41598-019-42087-z